Targeting of a novel fusion protein containing methioninase to the urokinase receptor to inhibit breast cancer cell migration and proliferation

详细信息    查看全文

• 作者：Karine Peron ; TaraN. Jones ; SebastienA. Gauthier ; Thao-NguyenT. Nguyen ; Xiao-Ping Zang ; Magali Barriere ; Damien Prévéraud ; CharlesE. Soliman ; RogerG. Harrison and J.Thomas Pento
• 关键词：Breast cancer ; Methioninase ; Urokinase ; Cancer targeting ; Fusion protein
• 刊名：Cancer Chemotherapy and Pharmacology
• 出版年：2003
• 出版时间：October 2003
• 年：2003
• 卷：52
• 期：4
• 页码：270-276
• 全文大小：296 KB
• 刊物类别：Biomedical and Life Sciences
• 刊物主题：Biomedicine
  Cancer Research
  Pharmacology and Toxicology
  Oncology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1432-0843

文摘

It has been shown that methionine depletion inhibits tumor cell growth and reduces tumor cell survival. A novel fusion protein targeted specifically to tumor cells was developed. The fusion protein contained two components: the amino terminal fragment of human urokinase (amino acids 1–49) that binds to the urokinase receptor protein expressed on the surface of invasive cancer cells, and the enzyme l-methioninase (containing 398 amino acids) which depletes methionine and arrests the growth of methionine-dependent tumors. The influence of the fusion protein on the growth and motility of human breast cancer cells was examined using a culture wounding assay. It was determined that MCF-7 breast cancer cells, used in this study, were methionine-dependent and that the fusion protein bound specifically to urokinase receptors of the surface of the cancer cells. Further treatment of the cancer cells with fusion protein over the concentration range 10–8 to 10–6 M produced a dose-dependent inhibition of both the migration and proliferation index of MCF-7 cells in the culture wounding assay over a period of 1 to 3 days. The results of this study suggest that this novel fusion protein may serve as a prototype for specific targeting of methioninase and perhaps other cytotoxic agents to cancer cells.